PRAX-628
Sponsors
Praxis Precision Medicines Inc., Praxis Precision Medicines Inc., Praxis Precision Medicines Inc., Praxis Precision Medicines
Conditions
Focal EpilepsyFocal onset seizures or primary generalized tonic-clonic seizuresFocal onset seizures or primary generalized tonic-clonic seizures.HealthyIPS induced photoparoxysmal electroencephalogram response (IPS-induced PPR) in participants with epilepsy and IPS-induced PPR
Phase 1
Phase 2
A Phase 2, Single-Blind, Placebo-Controlled, Fixed-Sequence Design Trial to Evaluate the Photoparoxysmal Electroencephalogram Response, Safety, Tolerability, and Pharmacokinetics of PRAX-628 in Participants with Epilepsy and a Photoparoxysmal Electroencephalogram Response to Intermittent Photic Stimulation
CompletedCTIS2023-504803-10-00
Start: 2023-06-15End: 2024-03-14Target: 12Updated: 2024-03-15
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in
Adults with Focal Seizures (POWER 1)
RecruitingCTIS2024-514559-13-00
Start: 2024-11-26Target: 170Updated: 2025-12-22
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures
CompletedCTIS2024-517061-16-01
Start: 2025-02-27End: 2025-11-07Target: 35Updated: 2025-10-27
Phase 3
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.
RecruitingCTIS2025-521640-38-00
Start: 2025-10-16Target: 56Updated: 2025-10-10
A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures
Not yet recruitingCTIS2025-524038-24-00
Target: 12Updated: 2026-04-10